Event

Outcomes research and quality improvements in lung cancer use a range of data sources including clinical trials, administrative and insurance-linked registries. The complexities of lung cancer screening call for high quality, accessible and relevant information, requirements that demand much of routinely collected clinical data. Administrative registries have advantages (large numbers, population cohorts) and disadvantages (retrospective, inaccessible). For many practicing lung cancer clinicians, registry data are not clinically relevant, despite the high levels of expenditure and effort required for their collection. This session will explore clinically relevant approaches to registry data that attendees can use to improve lung cancer outcomes.